Kathy High (AskBio)

'Gene ther­a­py is at an in­flec­tion point': Kathy High on her new perch at AskBio and the field­'s fu­ture

Kathy High need­ed some time off.

It had been six fren­zied years since she co-found­ed Spark Ther­a­peu­tics, 15 since she first pitched her Chil­dren’s Hos­pi­tal of Philadel­phia col­league Jean Ben­nett on start­ing a tri­al for what would even­tu­al­ly be­come the first ap­proved gene ther­a­py in the Unit­ed States. When Roche fi­nal­ly closed their $4.3 bil­lion buy­out of Spark last Feb­ru­ary, High qui­et­ly ex­it­ed for a sab­bat­i­cal at Rock­e­feller Uni­ver­si­ty in Man­hat­tan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.